Eledon's Tegoprubart Shows 100% Insulin Independence in Diabetes Study; Q1 Net Loss Widens
ELDN has more than doubled off its 52-week low of $1.35.
Summary
Eledon Pharmaceuticals reported its first quarter 2026 financial results and significant business highlights for its lead candidate, tegoprubart. The most impactful news is the achievement of 100% insulin independence in 10 patients with type 1 diabetes following islet transplantation in a UChicago Medicine-led study, alongside positive 24-month follow-up data from a Phase 1b kidney transplantation trial and FDA Orphan Drug designation for liver transplantation. Financially, the company reported a widened net loss of $39.0 million, or $0.33 per share, for Q1 2026, primarily driven by a $19.0 million non-cash loss from warrant liabilities. Cash, cash equivalents, and short-term investments totaled $111.1 million as of March 31, 2026, with a projected runway into Q2 2027. This cash position and burn rate reinforce the context of the $500 million universal shelf registration (S-3) filed on May 1st. The strong clinical data, particularly the 100% insulin independence, is a significant positive catalyst for a clinical-stage biotech, validating tegoprubart's potential and de-risking its development. Investors will now watch for upcoming FDA guidance on Phase 3 kidney transplantation trials and regulatory discussions for islet cell transplantation.
At the time of this announcement, ELDN was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $294.3M. The 52-week trading range was $1.35 to $4.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.